Speaker Profile

Ph.D., Professor, UCSF

Biography
Dr. Laura van ‘t Veer is a world-renowned molecular biologist whose research focuses on precision medicine to advance patient management. She is co-leader of the Breast Oncology Program at UCSF and co-founder of Agendia Inc. As inventor of MammaPrint she has made a seminal impact on “rightsizing” the treatment of breast cancer. A recent publication on the MINDACT trial shows that 46% of breast cancer patients who are clinically high risk and considered for chemotherapy, can safely forgo this treatment based on a Low Risk MammaPrint result. Dr. van ‘t Veer is co-PI of the multicenter adaptive clinical trial I-SPY2 overseeing FDA-IDE ‘Response-Predictive-Subtyping’ companion diagnostics. She has over 300 peer-reviewed scientific articles and is co-inventor of 9 patents. Dr. van 't Veer received the prestigious European Union Women Innovator Award, 2nd prize in 2014, the 2015 European Patent Office Inventor Award, and is a 2020 PMWC Luminary award recipient.


 Session Abstract – PMWC 2022 Silicon Valley

Track 3, June 28


Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.